Investor PresentationJanuary 2015

OIS MeetingOctober 2016

HypertensionDaily systemic doses

DiabetesInsulin Pump

ArthritisTherapy, exercise and at home medication

How Chronic Diseases are Treated Today

Low patient burden,continuous treatment

Bolus injections that last for 1-3 months administered directly to the eye by a physician, with reinjection every 1-3 months.

Ophthalmologists have adopted a standard of care that is inconsistent with the way their fellow physicians in other disciplines treat chronic diseases because their options have been limited.

How DME is Treated Today

High patient burden,intermittent treatment

22 © 2016 Alimera Sciences, All Rights Reserved2

33 © 2016 Alimera Sciences, All Rights Reserved3

ILUVIEN is the only therapy that allows physicians to consistently treat DME daily

InnovativeDelivery

44 © 2016 Alimera Sciences, All Rights Reserved4

Key DME Management Goals

1. A dry macula

2. Preservation of vision/improving sight

3. A reduction in the burden on the patient in terms of the frequency of injections and adverse events.

55 © 2016 Alimera Sciences, All Rights Reserved5

A dry macula Preservation of vision &/or

improving sight

Reduction in patient burden

1 2 3

Consistent Delivery With Sustained EffectILUVIEN® Delivers Consistent Treatment

66 © 2016 Alimera Sciences, All Rights Reserved6

Source:(a) OZURDEX® data from European Medicines Agency Assessment Report(b) ILUVIEN® data from Phase III Clinical Trials (FAME)

Side effects of steroids are known

• ILUVIEN brings innovation to ophthalmology

• Side effects are mitigated by applying the lowest possible dose

• Real world evidence indicates our success

77 © 2016 Alimera Sciences, All Rights Reserved7

HOWEVERILUVIEN is not the steroid of yesterday

Location N° of eyes (pts) Follow-up IOP Change & management

Medisoft 2nd data extract results (13 sites in the UK)1

290 Eyes (258 pts)

Up to

763days

a. IOP elevation >30 mmHg, 6.6%b. Emergent IOP-lowering drops, 14.8%c. Rate of trabeculoplasty, 0% d. Rate of incisional surgery, 0%

IRISS 2nd data extract (37 units in UK, DE, PT)2 328

Eyes (292 pts)

Up to

763days

a. IOP elevation >30 mmHg, 8.2%b. Emergent IOP-lowering drops, 18.4%c. Rate of laser trabeculoplasty, 0% d. Rate of incisional surgery, 0.6%

ILUVIEN Real-World Data Studies

1. Bailey C. Alimera Sciences symposium at EURETINA 2015.2. Chakravarthy U. Alimera Sciences Advisory Board held on March 12 2016 in Paris, France.88 © 2016 Alimera Sciences, All Rights Reserved8

99 © 2016 Alimera Sciences, All Rights Reserved9

Financial OverviewAs of 6/30/16

1010 © 2016 Alimera Sciences, All Rights Reserved10

Q1 Q2

$7.2M U.S.

$2.3MInternational

$4.1M U.S.

$1.7MInternational

2016 Revenue Growth

(a) Includes Series A preferred stock and warrants, Series B preferred stock, common stock warrants, stock options and common stock.

Q2 2016 Revenue

$9.5MQ2 2016 Gross Margin

94.2%Q2 2016 Net Loss

($6.9M)Cash & Cash Equivalents*

$42.0MDebt Outstanding

$35M* The number shown for Cash & Cash Equivalents is a pro-forma representation including net cash raised of $25.4M in the Company’s latest equity raise

Investor PresentationJanuary 2015

OIS PresentationOctober 2016